Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection

Viral Infection Clinical Trial

Official title: Modulating Endoplasmic Reticulum Stress as a Prophylactic Approach Against Symptomatic Viral Infection

Status Completed

Clinical Trial Summary

To determine the efficacy of metformin in reducing the rate of symptomatic YF17D infection, and to elucidate the effects of metformin on YF17D viremia and the downstream adaptive immune response, we hereby propose a randomised, double-blind, placebo-controlled clinical trial that is coupled with a system biology approach. We plan to recruit 44 healthy volunteers aged 21-40 years, with a Body Mass Index of 20-25 kg/m2, have no known drug allergies and are not currently receiving regular immune-modulating therapy such as metformin, NSAIDs, paracetamol, corticosteroids or statins. The age range that we propose will ensure that our volunteers are likely to be healthy and not be on long-term medication for other concurrent medical conditions. This would abrogate the confounding effect of YF17D infection enhancement by cross reactive antibodies that we have previously shown.

Informed written consent will be obtained before any physical examination is performed. All consented subjects will undergo screening which includes a full physical examination, vital signs measurement, clinical laboratory tests and urine pregnancy test (for female subjects of child-bearing potential) Eligible subjects will be randomized 1:1 to either metformin 1000mg or placebo twice daily for 7 consecutive days (Days 1-7). On Day 4, subjects will be administered one dose of YF17D before study drug dosing.

Aim 1 tests the hypothesis that prophylactic metformin reduces ER stress and thus attenuates the post-infection pro-inflammatory response for reduced rate of symptomatic outcome. The primary objective for Aim 1 is to determine the efficacy of metformin in reducing the rate of symptomatic YF17D infection using a randomized placebo-controlled clinical trial.

Aim 2 explores the effectiveness of metformin, either through its action on ER stress or other pathways that differentially regulate the expression of pro- and anti-viral host factors, in inhibiting live attenuated vaccine infection and downstream adaptive immune responses. The primary objective for Aim 2 is to elucidate the effects of metformin on YF17D viremia and the downstream adaptive immune response.

Clinical Trial Description

Criteria for Recruitment and Recruitment Process: Subjects will be recruited from SingHealth Investigational Medicine Unit (IMU) healthy volunteer database and recruitment posters. Subjects will be given a copy of the Participant Information and Informed Consent Form to read upon their arrival. A briefing session on the study will be conducted by the Investigator. Thereafter, subjects will be ushered into a private room where informed consent is obtained and where questions about the study can be asked freely. Subjects will not be rushed into making a decision to participate in the study. They will be encouraged to speak to their family members about participation in the study; and allowed to defer their decision (without any prejudice) to participate till after discussion with their family members.

Screening Visits and Procedures: Subjects will be recruited via the SingHealth Investigational Medicine Unit (IMU). Informed written consent will be obtained before any study related procedure or assessment is performed. All subjects' eligibility for recruitment into the study must be assessed during screening visit. Subjects must satisfy all inclusion and exclusion criteria outlined in Section 3.3 and Section 3.4 respectively to be eligible for enrolment into the study. Eligibility criteria must be confirmed before dosing. All clinical laboratory tests scheduled for screening will be collected to establish pre-dose baseline. Other procedures that must be completed before the study begins include a full physical examination and urinary pregnancy test (for female subjects of child-bearing potential).

Study Visits and Procedures: All eligible subjects will proceed to Day 1, where they will be randomized 1:1 to either metformin 1000mg or placebo twice daily for 7 consecutive days (Days 1-7). On Day 4, subjects will be administered one dose of YF17D before study drug dosing. Subjects will report to the SingHealth IMU on Day 1 (pre-study drug), Day 4 (pre-YF17D), Days 5, 7, 11, 14, 18 (only for participants who consent to scRNA-seq and T-cell studies) and Day 32 for research blood sampling. The schedule for blood draws will be identical for all study groups. All research blood samples will be stored at -80oC until recruitment is completed before analysis. Subject recruitment and blood collection will be conducted as an outpatient study in the SingHealth Investigational Medicine Unit (IMU), a dedicated early phase clinical trial facility. From our prior experience, we anticipate we will not have difficulty recruiting the required number of participants into our study necessary to meet our target sample size.

Post Study Follow up and Procedures: There is no requirement for post-study follow-up or procedures.

Safety Monitoring Plan: The study may be evaluated by government inspectors/regulatory authorities who must be allowed access to e-CRFs, source documents, and other study files. The inspectors will review CRFs and compare them with source documents to verify accurate and complete collection of data and confirm that the study is being conducted according to the protocol, ICH-Good Clinical Practices (ICH-GCP) and all applicable regulations.

Known common adverse events of metformin include diarrhoea, nausea, stomach pain, heartburn and bloatedness. Rare AEs include lactic acidosis and hypoglycaemia. Limiting the duration of metformin dosing to 10 days would further reduce the risk of these serious AEs. Subjects will be trained to look out for early symptoms associated with these AEs and to report to IMU immediately should they experience any of these symptoms. Details of AE event terminology, date and time of event start and end, severity, using the CTCAE or treatment given, impact on work and to the continuation of the study, and final outcome of the event will be recorded on the case report until resolution of the event.

During the study, the investigator will recruit the subjects, as well as perform full history taking and physical examination at both scheduled and unscheduled visits. The investigator will also review the subject's diaries for any potential side effects and manage the AEs based on best clinical practice should they arise. Compliance to study protocol will be checked by taking a medication history, and pill count and inspection of diary as well as measurement of metformin drug level at specific time points.

Data Quality Assurance: The PI and Co-Is will review the study periodically for data and safety monitoring. Internal quality checks will be performed by two CRCs who are study team members. The data entered by one CRC will be checked by another using the source documents. The study may also be picked for monitoring by SingHealth Office of Research Integrity and Compliance (ORIC) or evaluated by government inspectors/regulatory authorities who must be allowed access to e-CRFs, source documents, and other study files. The monitors/inspectors may review CRFs and compare them with source documents to verify accurate and complete collection of data and confirm that the study is being conducted according to the protocol, ICH-Good Clinical Practices (ICH-GCP) and all applicable regulations.

Data Entry and Storage: All participant's data will be de-identified upon recruitment. Hardcopy research data collection forms such as CRFs, logs and diaries will be kept in the Investigator's Site File and stored in SingHealth IMU under lock and key, accessible only to delegated study team members. Direct data capture of demographic and clinical data will be captured on source documents. Identifiers will be kept in a separate file in another office and every effort will be made to protect the privacy of the participants. The data to be analysed will contain only de-identified data. An electronic data capture system will be used. All electronic data will be password protected and can only be accessed by study team members. Specimens, test results or pathogen data will be stored at Duke-NUS EID laboratory in a stand-alone PC whereby access is password protected.

Determination of Sample Size: A sample size of 20 per arm will give 80% power to detect a reduction in systemic symptoms from 50% to 10% (risk difference = 0.4 reduction ratio = 0.8) in participants who receive placebo versus who are pre-treated with metformin versus placebo group at a 2-sided 5% type I error rate (PASS 13 Software). Factoring in a potential dropout rate of 10%, the total sample size is 44 in total (22 per arm). From our previous experience with subject recruitment in the YF vaccine trial, there were no dropouts during the 1-month follow-up period. Therefore, we are confident that we can recruit the required number of subjects within the trial period.

Statistical analysis: Fisher's exact test will be used to assess difference in systemic symptom rate between placebo and metformin pre-treatment arm. Confidence intervals (CI) for AE rates will be estimated using the exact method. CI for risk difference will be estimated using the Newcombe's score method.

Diagnostic plots will be used to determine the choice of using the raw data or log-transformed data in parametric analyses or non-parametric analyses. Differences in anti-YF neutralizing antibody titer at day 28, viremia and SBREP-1 expression will be compared between placebo and metformin groups. Relationship between systemic symptoms, molecular correlates of immunogenicity, viremia, antibody titer and metformin will be explored with regression methods. Differences in background characteristics between subjects who do and do not have systemic symptom onset will be included in covariate-adjusted analysis.

Determination of study drug blood level: Study drug levels will be measured via a liquid chromatography-tandem mass spectrometric (LC-MS/MS) assay method. The assay will be performed on a Shimadzu 8060 LC-MS/MS system, which is available at the Singapore General Hospital.

Gene expression studies: Gene expression in whole blood would be carried out using Nanostring nCounter assay. This assay provides a multiplex approach to identify the genes that the investigator have previously used to validate the hits from the microarray that identified adaptive ER stress as a susceptibility factor for symptomatic YF17D infection (see preliminary data). Importantly, the investigator have worked with Nanostring, to customize a comprehensive set of probes that are able to directly quantify mRNA transcripts in the ER stress and TCA cycle pathways, which would be the target genes in this trial. This approach is also chosen due to the CSA budget constraint. Nonetheless, the study team will collect extra clinical samples as backup and explore the use of RNAseq to discover the pharmacogenomics of metformin through additional funding from other grant sources.

This proposed gene expression study will be carried out at the Viral Research and Experimental Medicine Centre @ SingHealth Duke-NUS (ViREMiCS). ViREMiCS was established by the PI and collaborator, Eng Eong Ooi as a research centre in the SingHealth Duke-NUS Academic Medicine Centre partnership. It has established a suite of molecular and systems biology tools to support and accelerate proof-of concept clinical trials. The investigators thus do not anticipate any problem in using this approach to measure gene expression in blood samples.

Proteomics and Metabolomic profiling: Plasma metabolomics will be examined using capillary electrophoresis/mass spectrometry (CE/MS), and liquid chromatography/mass spectrometry LC-MS/MS as we have previously employed to measure the polar metabolites from glycolysis and TCA cycle [18, 25]. Proteomics will be measured using LC-MS/MS. These assays will be carried out using the core equipment available in the Programme in Emerging Infectious Diseases and Metabolomics Core Facility, both in Duke-NUS. This will enable a multi-omics approach to support enhanced biological insights.

Chemokine and Cytokine: Serum chemokine and cytokine levels will be measured using the Luminex or Olink assay that enables more than 40 serum chemokines and cytokines to be measured simultaneously.

YF Viremia and PRNT titres: YF viremia loads will be assessed using quantitative real-time PCR (qRT-PCR). Anti-YF neutralising antibody titres will be measured by plaque reduction neutralisation test (PRNT). Briefly, 50 PFU (plaque forming units) of YF17D virus will be incubated with 2-fold serial dilutions of human serum for one hour at 37oC, and then added to a monolayer of Vero cells in 24-well plates. One hour later, media will be aspirated and cells overlaid with carboxymethyl cellulose 1% in maintenance media. After 5 days, cells will be fixed, washed and stained with crystal violet. The number of plaques will be counted and PRNT50 titres determined using a sigmoid dose-response curve fit as reciprocal values.

scRNA-seq and T-cell Studies: Single cell RNA sequencing (scRNA-seq) will be performed on PBMCs isolated before and after metformin treatment to determine the impact of metformin treatment on different immune cell subsets. This proposed study will be carried out in collaboration with the Genome Biology Facility at Duke-NUS. Subsequently, using the findings of scRNA-seq as a guide, we will then assess T-cell function and activity using either flow cytometry or enzyme-linked immune absorbent spot (ELISPOT) assay. These assays will be carried out using core equipment available in the Programme in Emerging Infectious Diseases in Duke-NUS. ;

Related Conditions & MeSH terms

• Communicable Diseases
• Endoplasmic Reticulum Stress
• Infections
• Viral Infection
• Virus Diseases
• Yellow Fever

• NCT number: NCT04267809
• Study type: Interventional
• Source: Singapore General Hospital
• Status: Completed
• Phase: Phase 2
• Start date: October 22, 2021
• Completion date: July 31, 2023